Shown values refer to:
Age: All age-groups
ATC-group (2nd level) | Year (descending) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
2006 | 2010 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
Overall market of statutory health insurance (GKV) prescriptions with manufactured drugs | 418.6 | 507.2 | 568.7 | 574.7 | 571.1 | 568.5 | 600.1 | 616.9 | 630.4 | 645.1 |
A01 Stomatological preparations | 3.2 | 1.1 | 6.0 | 6.3 | 6.4 | 5.9 | 6.5 | 6.1 | 6.1 | 5.8 |
A02 Ulcer therapeutics | 18.7 | 34.1 | 53.1 | 54.6 | 51.5 | 49.9 | 50.8 | 51.2 | 52.0 | 52.1 |
A03 Spasmolytics | 1.2 | 1.3 | 0.9 | 0.9 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 |
A04 Antiemetics | 0.1 | 0.1 | 0.1 | - | - | - | - | - | - | - |
A05 Gallen-/Lebertherapeutika | - | - | - | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
A06 Laxatives | 0.8 | 1.0 | 1.2 | 1.3 | 1.3 | 1.3 | 1.3 | 1.4 | 1.5 | 1.4 |
A07 Antidiarrheals | 1.0 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.6 |
A09 Digestiva | - | - | - | - | - | - | - | - | - | 0.3 |
A10 Antidiabetics | 24.2 | 29.7 | 30.2 | 30.6 | 30.6 | 30.3 | 31.9 | 33.2 | 34.1 | 36.8 |
A11 Vitamins | 4.3 | 4.6 | 7.0 | 7.5 | 7.9 | 8.0 | 8.1 | 8.8 | 9.4 | 9.3 |
A12 Minerals | 2.0 | 2.2 | 1.7 | 1.6 | 1.5 | 1.4 | 1.5 | 1.4 | 1.3 | 1.2 |
B01 Antithrombotical agents | 14.7 | 18.5 | 23.2 | 23.8 | 24.0 | 24.3 | 26.0 | 27.0 | 27.2 | 27.2 |
B03 Antianemic combinations | 2.3 | 2.8 | 3.8 | 4.1 | 4.2 | 4.3 | 4.5 | 4.4 | 4.5 | 4.6 |
B05 Blood substitute drugs and perfusion solutions | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
C01 Cardiac therapeutics | 13.0 | 9.6 | 6.2 | 5.7 | 5.3 | 4.8 | 4.7 | 4.6 | 4.3 | 4.2 |
C02 Antihypertensives | 4.6 | 4.9 | 5.0 | 5.0 | 4.9 | 4.8 | 5.1 | 5.2 | 5.3 | 5.3 |
C03 Diuretics | 25.8 | 28.0 | 26.5 | 26.1 | 25.4 | 24.7 | 25.7 | 26.3 | 26.0 | 25.7 |
C04 Peripheral vasodilators | 0.8 | - | - | - | - | - | - | - | - | - |
C05 Vasoprotectives | 0.3 | 0.3 | 0.2 | - | - | - | - | - | - | - |
C07 Beta-receptor blocker | 28.2 | 32.6 | 31.9 | 31.2 | 30.4 | 29.2 | 29.7 | - | - | 28.7 |
C08 Calcium antagonists | 21.7 | 28.3 | 30.0 | 30.5 | 30.6 | 30.7 | 33.4 | 35.3 | 36.1 | 36.7 |
C09 Angiotensin inhibitor | 68.5 | 104.2 | 122.5 | 124.5 | 125.1 | 126.2 | 136.4 | 142.2 | 144.8 | 147.5 |
C10 Antilipemics | 27.2 | 23.7 | 28.9 | 30.7 | 31.9 | 33.4 | 37.4 | 41.3 | 45.6 | 49.5 |
D01 Antifungals (topical) | 1.0 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
D02 Hautschutzmittel | - | - | - | - | - | - | - | 0.4 | 0.4 | 0.5 |
D04 Antipruriginous agents | 0.4 | - | - | - | - | - | - | - | - | - |
D05 Antipsoriatika | - | - | - | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.8 |
D06 Antiinfectives (dermatological) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 |
D07 Corticosteroids (dermatological) | 3.6 | 3.8 | 4.4 | 4.5 | 4.5 | 4.5 | 4.7 | 4.9 | 5.0 | 5.0 |
D10 Anti-acne preparations | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.8 | 0.7 |
D11 Other dermatological preparations | 0.7 | 0.7 | 0.9 | 1.0 | 1.0 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 |
G01 Gynaecological antiinfectivs | 0.1 | 0.1 | 0.1 | - | - | - | - | - | - | - |
G03 Sexual hormones | 16.3 | 14.7 | 12.7 | 12.1 | 11.6 | 11.2 | 12.5 | 12.9 | 14.7 | 14.8 |
G04 Urological drugs | 4.9 | 7.7 | 9.2 | 9.4 | 9.4 | 9.5 | 10.1 | 10.4 | 10.7 | 10.8 |
H02 Corticosteroids (systemic) | 5.1 | 5.8 | 6.1 | 6.1 | 6.1 | 6.0 | 6.2 | 6.0 | 5.9 | 6.0 |
H03 Thyroids therapeutics | 18.9 | 21.9 | 25.1 | 25.2 | 25.1 | 24.8 | 25.7 | 26.2 | 25.9 | 25.9 |
J01 Antibiotics | 4.7 | 5.1 | 5.2 | 5.2 | 4.6 | 4.3 | 4.1 | 3.3 | 3.0 | 3.7 |
J05 Antivirals | 0.4 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 |
Vaccines | - | 0.0 | 0.0 | 0.0 | - | - | - | - | - | - |
L01 Antineoplastic Agents | - | - | - | - | 1.0 | 0.9 | 1.0 | 1.1 | 1.2 | 1.2 |
L02 Hormone antagonists | 1.7 | 2.0 | 2.0 | 2.1 | 2.1 | 2.1 | 2.2 | 2.3 | 2.3 | 2.4 |
L03 Immunostimulants | 0.4 | 0.4 | - | 0.3 | 0.3 | - | - | - | - | - |
L04 Immunosuppressants | 1.0 | 1.2 | 1.6 | 1.8 | 2.0 | 2.2 | 2.5 | 2.7 | 2.9 | 3.2 |
M01 Antiphlogistics/anti-inflammatory drugs | 12.9 | 15.3 | 15.7 | 15.5 | 14.7 | 14.3 | 14.6 | 14.0 | 14.2 | 15.2 |
M02 Anti-inflammatory agens (topical) | 0.3 | - | - | - | - | - | - | - | - | - |
M03 Muscle relaxants | 1.2 | 1.9 | 1.6 | 1.6 | 2.0 | 2.1 | 2.3 | 2.3 | 2.5 | 2.7 |
M04 Gout agents | 5.0 | 5.2 | 5.4 | 5.4 | 5.3 | 5.2 | 5.3 | 5.2 | 5.1 | 4.9 |
M05 Osteoporosis agents | 2.3 | 3.2 | 3.0 | 3.0 | 2.9 | 2.9 | 3.0 | 3.1 | 3.1 | 3.1 |
M09 Antiarthrotika/andere Mittel | - | - | - | - | - | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 |
N02 Analgesics | 6.9 | 8.6 | 9.1 | 9.3 | 9.3 | 9.1 | 9.5 | 9.9 | 10.1 | 13.0 |
N03 Antiepileptics | 3.4 | 4.6 | 5.7 | 5.8 | 5.9 | 5.9 | 6.4 | 6.7 | 6.8 | 4.4 |
N04 Anti parkinson drugs | 1.8 | 2.1 | 2.2 | 2.2 | 2.1 | 2.1 | 2.2 | 2.2 | 2.2 | 2.1 |
N05 Psycholeptics | 8.2 | 8.3 | 7.9 | 7.7 | 7.6 | 7.4 | 7.6 | 7.7 | 7.7 | 7.6 |
N06 Psychoanaleptics | 13.0 | 19.4 | 23.0 | 23.1 | 23.2 | 23.3 | 24.7 | 25.6 | 26.3 | 27.1 |
N07 Anti vertiginous and addiction therapeutics | 1.2 | 1.3 | 1.6 | 1.6 | 1.7 | 1.6 | 1.6 | 1.7 | 2.0 | 2.6 |
R01 Rhinologic drugs | 3.5 | 3.9 | 4.3 | 4.3 | 3.7 | 3.6 | 3.7 | 3.1 | 3.3 | 4.1 |
R03 Anti-asthma medication | 16.7 | 18.3 | 18.2 | 18.2 | 18.1 | 18.0 | 19.0 | 19.4 | 19.2 | 19.7 |
R05 Cough and cold preparations | 2.6 | 2.1 | 1.6 | 1.5 | 1.4 | 1.3 | 1.2 | 0.9 | 0.9 | 1.2 |
R06 Antihistamines | 1.6 | 1.4 | 1.5 | 1.6 | 1.5 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 |
S01 Ophthalmic drugs | 9.4 | 9.6 | 10.6 | 10.8 | 10.9 | 10.9 | 11.5 | 11.2 | 11.4 | 11.8 |
S02 Otologicals | 0.3 | 0.2 | 0.2 | - | - | - | - | - | - | - |
V01 Allergens | - | - | - | 1.9 | 2.0 | 2.0 | 2.1 | 2.3 | 2.4 | 2.3 |
The Federal Health Monitoring System 19. Apr 2024